Tagged with

Denmark Peter Jorgensen, Director of the Danish Generic and Biosimilar Medicines Industry Association, discusses Denmark’s robust framework for generics and biosimilars, offering insight into a system that has delivered high penetration, cost savings, and broad public trust. From legal structures and patient attitudes to incentives and hospital adoption, Jorgensen outlines why…

Switzerland Amid a crowded landscape of incremental innovation, Synendos Therapeutics stands out for its bold approach to neuropsychiatric drug development. Co-Founder and CEO Andrea Chicca shares how the company emerged from a translational research programme in Switzerland to pioneer a first-in-class therapeutic strategy targeting the endocannabinoid system, a master regulator of…

France The biggest recent stories from French healthcare and the life sciences, including Sanofi’s deal to buy immunology biotech Blueprint; the largest from a European pharma this year. Elsewhere Servier is snapping up a experimental leukaemia treatment from China, while French tech firm OWKIN is touting a new “AI-powered research co-pilot”…

Hong Kong In March 2024, the Advanced Therapy Product Good Manufacturing Practice Centre (ATP GMP Centre) at the Chinese University of Hong Kong’s (CUHK) Institute of Biotechnology (HKIB) became the first university-led centre within the special administrative region to receive certification for cell and gene therapy manufacturing and a license as an…

Europe Lora Fleifel, Director of Global Value Access & Pricing Operations Europe for Oncology at Merck, dissects the promise and pitfalls of the new EU Joint Clinical Assessment (JCA). The JCA aims to harmonise clinical evaluations to help reduce the significant disparities in patient access to innovative treatments that still exist…

China Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and no initial products, OcuMension now leads in China’s ophthalmology drug development, maintains rapid growth, and is preparing for global reach.…

USA Having terminated dozens of HIV-related research grants, the Trump administration’s assault on the field continues. In a major blow to the decades-long search for a vaccine, the US federal government has pulled the plug on the HIV vaccine programme run by the US National Institute of Health (NIH) –the world’s…

Denmark As Denmark launches its ambitious Life Science Strategy 2030, the Danish Medicines Agency (DKMA), long held as the embodiment of European regulatory excellence, is fine-tuning its priorities. New director Nils Falk Bjerregaard sees the DKMA’s role as a “facilitator of innovation,” supporting early-stage development and leveraging real-world data at home,…

Switzerland Matthew Brabazon, General Manager of EMEA at SFI Health, a global natural healthcare company, discusses the company’s shift towards branded products and its focus on clinically supported products in the areas of cognition and the microbiome sector. What sets us apart is simple: our products are clinically substantiated. We walk…

Germany A summary of some of the top stories coming out of Germany’s biopharma industry, including Bayer’s EMA win for its Eylea eye therapy; the oncology deal Merck KGaA has cut with SpringWorks Therapeutics; the bispecific antibody alliance between BMS and BioNTech, and Sartorius’ acquisition of microtissue firm MatTek.   Bayer…

Global Writing in ISPOR’s Value and Outcomes Spotlight magazine, Beth Fand Incollingo looks at why health economics and outcomes research may hold the key to solving some of healthcare’s most entrenched access and affordability issues.   Healthcare can only be widely effective if most patients can access and afford it. Yet,…

China Building a biotech from the ground up is rarely the next step for someone who has led multinational pharmaceutical giants. Yet that was the challenge Pony Lu accepted when he took the helm at VISEN Pharmaceuticals. Tasked with shaping the company from its inception, he brought not only decades of…